Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
3 biotech powerhouses poised to thrive amid sector rebound
10:11am, Friday, 08'th Dec 2023
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally a
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
07:45am, Friday, 08'th Dec 2023
Regeneron has a strong and diverse business with a couple of key assets in Eylea and Dupixent. The company also has dozens of trials ongoing that can further bolster its growth prospects.
Calls Of The Day: Autozone Deere and Regeneron named top picks
01:15pm, Wednesday, 06'th Dec 2023
Autozone, Deere, Regeneron and Apollo Global getting some bullish calls today. The Investment Committee debates what it means for the stocks and how to trade them.
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
08:28am, Tuesday, 05'th Dec 2023
Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
04:05pm, Thursday, 30'th Nov 2023
TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
12:02pm, Monday, 27'th Nov 2023
Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.
3 Biotech Stocks To Watch Before December 2023
10:38am, Monday, 27'th Nov 2023
Biotech stocks to check out in the stock market today.
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
12:49pm, Friday, 24'th Nov 2023
Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.
HRMY vs. REGN: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 21'st Nov 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s
Regeneron Announces Investor Conference Presentation
04:05pm, Wednesday, 15'th Nov 2023
TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)
01:15pm, Saturday, 11'th Nov 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET Company Participants Dr. Len Schleifer - President and Chief Executive Officer Ryan Cro
Regeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)
12:49pm, Saturday, 11'th Nov 2023
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Brook Jennings - Vice Pres
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 03'rd Nov 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is mor
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript
01:14pm, Thursday, 02'nd Nov 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer –
